BioConnect Iowa’s 2020 Annual Report, January 13, 2021 by unknown

Like all of society, Iowa Innovation Corporation’s / BioConnect Iowa’s activities in 2020 
were disrupted by the COVID-19 pandemic. Through the dedication of staff and partners 
during this challenging year, significant steps were taken towards delivering on the 
organization’s mission to foster the growth of Iowa’s bioscience sector.
First, renaming and rebranding of the corporation was completed to form BioConnect 
Iowa (BCI). BCI adopted the tagline “We move ideas forward.” The corporation believes 
its new name and associated logo captures well the bioscience focus adopted in 2018 and 
aligns with its mission. A new website (bioconnectiowa.org) was also launched. We are 
grateful to deNovo Marketing for the work they did on this project and the outstanding 
results.
Second, in September, BCI was notified that it received a three-year award from the U.S. 
Economic Development Administration (EDA) under the Build to Scale (B2S) program 
(eda.gov/oie/buildtoscale/). This grant, worth over $1.2M over the three-year period, will 
allow BCI and its partners on the project, Iowa State University (ISU) Startup Factory and 
VentureNet Iowa, to develop and launch a new startup accelerator program and online 
resource guide.
Third, to continue building on momentum from FY 2020, BCI augmented the FY 2021 
state appropriation of ~$1.08M to ISU and University of Iowa (U of I) for bioscience 
efforts with an additional $1M ($750K to ISU; $250K to U of I), enabling expansion of 
both universities’ efforts. This one-time reallocation of funds that the Iowa Economic 
Development Authority set aside for BCI under the current funding contract demonstrates 
BCI’s ongoing recognition of the importance of these university partnerships. An increased 
state appropriation will again be sought for FY 2022.
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BIOSCIENCE PLATFORMS
BIOBASED CHEMICALS / PRODUCTS 
PLATFORM (ISU PARTNERSHIP)
This platform received most of the funding at ISU during 
FY2020. Over the past year, progress has been made on 
several fronts.
ISU Chief Technology Officer (CTO) Sundeep Vani 
and BCI Commercial Officer Steve Smith serve as 
advisors for a recently founded ISU spin-off company, 
SoyLei Technologies (soylei.com), which has licensed 
technology developed at ISU in the labs of Dr.’s Eric 
Cochran and Chris Williams. SoyLei’s InvigoSoy Asphalt 
Paving Rejuvenator outperforms the petroleum-
based competition by multiple measures. InvigoSoy 
(along with related technologies) has the potential 
to provide a sizeable new market for soybeans and a 
biorenewable source of this asphalt component. SoyLei is 
commercializing this technology through a marketing and 
sales partner and will have revenue during their first year 
of operation.
In late 2020, the U.S. Department of Defense announced 
an $87M, seven-year award to the “BioIndustrial 
Manufacturing and Design Ecosystem” (BioMADE) 
for a new Manufacturing Innovation Institute to be 
headquartered at the University of Minnesota. ISU is a 
member and has played an important role in this initiative, 
coordinating discussions with several industry partners 
(Cargill, Novozymes, ADM, Genomatica, White Dog Labs). 
This award will provide the opportunity for ISU researchers 
to compete for funds for commercial development 
projects, with funding from the state and BCI leveraged as 
match.
My team and I have worked with 
BioConnect Iowa since formation of 
SoyLei in early 2020.  They’ve been 
helpful guiding us through the process 
of starting a new business. Their 
expertise and counseling have brought 
tremendous value to our start-up by 
always making sure that we found the 
answer to our problems. Their set of 
skills and experiences have proven to 
be exactly what we needed.
Nacu B. Hernadez, PhD
CEO, SoyLei Technologies
PRECISION & DIGITAL AGRICULTURE 
(ISU PARTNERSHIP)
In 2019, ISU and BCI engaged a market research company 
to help better understand the research priorities of leading 
companies in this sector, as well as to gain perspectives 
on the commercial landscape. This project was completed 
in early 2020. Several identified opportunities align well 
with ISU research strengths, including: (i) development of 
insect and disease models that can be used to optimize 
control strategies, (ii) sensor technologies and integration 
of sensor output data with other field monitoring/
management data, and (iii) potential creation of a service 
that can help provide field trial support for ag startups and 
facilitate industry connections.
Following up on the recommendations from this study 
requires having a platform CTO in place. Funding from 
BCI in FY 2021 enables this, and CTO recruitment is 
ongoing.
Finally, a seed grant program was initiated, and in 
November 2020, two grants were awarded for ISU 
researcher-industry collaborations. 
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MEDICAL DEVICES
(U OF I PARTNERSHIP)
Jon Darsee (U of I Chief Innovation Officer, with 
operational responsibility for this platform) is using 
the FY 2021 BCI funding to: (i) increase awareness and 
customer base across the state of UI Ventures, UI Research 
Foundation, Protostudios and MADE, (ii) help fill a one-
year gap in funding for support of early-stage product 
development research that falls outside the scope of 
typical research or commercial funding mechanisms, 
and (iii) fund a seed program for nurses in the UI Health 
Center that supports development of creative solutions to 
problems they see every day in clinical practice.
VACCINES AND IMMUNOTHERAPEUTICS 
(ISU PARTNERSHIP)
BCI funding in 2020 has enabled hiring of a platform 
CTO at ISU. In November, Mike Roof was named ISU 
Vaccines and Immunotherapeutics Platform CTO. Mike 
is currently engaging with faculty at ISU and the U of I to 
identify commercially promising projects and collaboration 
opportunities across the universities. The potential for 
such projects was demonstrated during 2020 with the 
award of $2M from CARES Act funding being made by 
the state to the ISU Nanovaccine Institute along with 
U of I and startups to collaborate on development and 
manufacture of second-generation COVID coronavirus 
vaccines.
The platform seed grant program initiated in 2019 
continued with one additional award made to-date for a 
collaborative project with LEAH Labs to investigate the 
use of targeted cell therapies for treatment of canine 
cancers. 
SMALL BUSINESS INNOVATION 
RESEARCH (SBIR) AND 
TECHNOLOGY TRANSFER 
OUTREACH (STTR) PROGRAM
The SBIR/STTR Outreach Program provides support for 
innovative Iowa businesses seeking federal grants through 
the Small Business Administration’s SBIR and STTR 
programs. This support is not restricted to bioscience 
companies. FY 2020 was another successful year for the 
SBIR/STTR Outreach Program on several fronts:
Forty-six applications were supported between July 2019 
and June 2020, with eight companies receiving eight 
awards, totaling $6.3M during this period. 
Breakdown of Iowa SBIR/STTR Outreach Program
Applications, FY2018 and FY2019
Phase I awards were won by 3D Health Solutions, Legov 
Systems Group, Senseion Therapeutics and NeoVaxSyn, 
while Infondrian, Omni-Life Health Tech Solutions, 
Viewpoint Molecular Targeting and Parametric Studio 
received grants for Phase II projects.
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Iowa SBIR/STTR Outreach Program Percentage of
Applications Recieving Awards, FY2019 and FY2020
The total number of applications in FY 2020 was down 
from recent years (see Table 1), primarily believed to 
be due to the impact the COVID-19 pandemic had on 
activities at all research institutions during the last ~four 
months of FY 2020. This belief is supported by the return 
to historical norms seen during the first half of FY 2021. A 
success rate of 17% is also towards the low-end of what 
has been seen over recent years. 









2020 8 46 $6.3M
2019 16 52 $4M
2018 19 86 $7M
2017 10 69 $5.8M
Iowa SBIR/STTR Outreach Program, Leveraged Federal
Funds FY2019
$6.3M in awards represents a $12.20 return in federal 
funds for every $1 invested by the state into application 
support and award matches, which is an all-time high 
and double what was seen in either FY 2018 or FY 2019. 
The reason for this is the increasing number of Phase II 
awards (typically much larger than Phase I awards) now 
being obtained by Iowa companies. BCI believes this is 
a natural progression of a successful program. Following 
initiation several years ago of the financial support 
program, the number of applications has increased. The 
combination of more applications and improved quality 
due to the technical support part of the program helped 
generate an increase in Phase I awards. The past few years 
brought a success rate of >15%-30%, compared with an 
average national success rate of ~15%. BCI is now seeing 
an increase in Phase II applications and awards, which 
resulted from successful execution of Phase I projects.
“We’ve appreciated support 
from BioConnect Iowa towards 
commercialization of our patient 
safety-centered software. The grant 
assistance program played a vital 
role in helping Infondrian secure 
a Phase I STTR award.  The STTR 
matching program helped enable the 
Infondrian team to perform market 
analysis, IP evaluation, and work 






This program was developed during 2019 to increase 
knowledge about the federal SBIR and STTR funding and 
state outreach programs across the state, by providing 
education and supporting materials to key entrepreneur 
support groups across the state. This program was 
rolled out as planned during 2020, although many of the 









FY 2019 FY 2020
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IOWA GO-TO-MARKET (G2M) PROGRAM
In June 2020, BCI submitted a proposal to the U.S. EDA 
for funding as part of their Build to Scale program. In 
September, BCI’s was notified that it received one of 52 
awards made in 2020, from over 600 grant applications. 
The ~$1.2M in total funding for the three-year program 
consists of ~$500K from the U.S. EDA, ~$450K in 
pro bono services, ~$250K in in-kind BCI and ISU 
contributions and $15K of State support. The program 
components aim to help address two gaps in ecosystem 
support that particularly impact research-driven high-
tech startups, which includes many in bioscience sectors. 
There is a broad consensus that many such companies 
could benefit from (i) additional structured entrepreneur 
support programs that follow the existing early-stage 
accelerators in the state, and (ii) improved connections 
with service providers that can help founders in multiple 
ways, including developing their businesses, securing IP 
and obtaining funding.
Funding from the grant is being used by BCI and its 
project partners, ISU Startup Factory and VentureNet 
Iowa, to support two initiatives that are believed to be 
able to help address the ecosystem gaps described:
G2M ACCELERATOR
A new accelerator program, with the same name as the 
funded project, is being launched in 2021 (iowag2m.org). 
This program targets existing Iowa startup companies 
that meet two criteria. First, the program is designed 
for companies developing technology-driven innovative 
products or services. Industry sectors typically represented 
will include (but not be limited to) biosciences, ag-tech, 
advanced manufacturing and tech/software. Second, 
the program targets startups that already received 
entrepreneurial guidance, preferably through a formal 
program. 
The program will be run by ISU Startup Factory personnel, 
with the application process run by VentureNet, modelled 
after what they developed and use for review of 
applicants for State Innovation funding. As of December 
2020, recruitment of the inaugural cohort is ongoing.
One unique component of this program is that over 10 
firms in areas like legal, finance and branding/marketing 
signed up to be part of the program through delivery of 
pro bono services to cohort companies. BCI believes this 
will have significant value for companies at the stage of 
development targeted by the program.
ONLINE RESOURCE GUIDE
Multiple online resource guides exist in Iowa, but none 
are focused on the needs of research-driven, high-tech 
startups. In partnership with VentureNet Iowa, BCI is 
developing a guide that will direct these companies (with 
unique characteristics of generally being IP-intense, often 
with long product development timelines and significant 
pre-revenue capital needs) to resources from across Iowa 
with experience working with these types of companies.
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